Trial · NCT00538980
Dasatinib in Polycythemia Vera
NCT00538980, Phase 2, Terminated, Weill Medical College of Cornell University; results first posted 2017-06-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib in Polycythemia Vera. Trials, record NCT00538980. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00538980
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib in Polycythemia Vera
- NCT number
- NCT00538980
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Weill Medical College of Cornell University
- Conditions
- Polycythemia Vera
- Interventions
- Dasatinib
- First posted
- 2007-10-03
- Last updated
- 2017-06-20
- Results first posted
- 2017-06-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of Dasatinib on the Platelet Count and the Stabilization of Hematocrit When Restored by Phlebotomy to Normal Range | Lab tests will be performed weekly for the first month, then every 2 weeks for months 2 and 3 and monthly thereafter. | To evaluate the effect of dasatinib on the platelet count and the stabilization of hematocrit when restored by phlebotomy to normal range (HCT \<45% for men, \<42% for women). Analysis was not completed because the study was terminated early due to lack of efficacy. |
| Primary | Change in Performance Status and Development of Side Effects and Complications | Patients will evaluated weekly for the first month, then every two weeks forr months 2 and 3, and monthly thereafter. | To determine change in performance status and development of side effects and complications in patients treated under this protocol. Analysis was not completed because the study was terminated early due to lack of efficacy. |
| Secondary | Changes in Marrow Cellularity, Reticulin and Fibrous Content | Bone marrow analysis will be performed at baseline and month 6. | To determine changes in marrow cellularity, reticulin and fibrous content. Analysis was not completed because the study was terminated early due to lack of efficacy. |
| Secondary | Change in Cytogenetics | Cytogenetics analysis will be performed at baseline and month 6. | To determine change in cytogenetics if initially abnormal. Analysis was not completed because the study was terminated early due to lack of efficacy. |
| Secondary | Change in JAK2 Allele Burden | JAK2 analysis will be performed at baseline and month 3. | To determine if quantitative change in JAK2 expression occurs as measured by quantitative pyrosequencing. Analysis was not completed because the study was terminated early due to lack of efficacy. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Effect of Dasatinib on the Platelet Count and the Stabilization of Hematocrit When Restored by Phlebotomy to Normal Range | Lab tests will be performed weekly for the first month, then every 2 weeks for months 2 and 3 and monthly thereafter. | |||
| PRIMARY | Change in Performance Status and Development of Side Effects and Complications | Patients will evaluated weekly for the first month, then every two weeks forr months 2 and 3, and monthly thereafter. | |||
| SECONDARY | Changes in Marrow Cellularity, Reticulin and Fibrous Content | Bone marrow analysis will be performed at baseline and month 6. | |||
| SECONDARY | Change in Cytogenetics | Cytogenetics analysis will be performed at baseline and month 6. | |||
| SECONDARY | Change in JAK2 Allele Burden | JAK2 analysis will be performed at baseline and month 3. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Patients | 10 | |
| Overall Study | COMPLETED | All Patients | 0 | |
| Overall Study | NOT COMPLETED | All Patients | 10 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Dyspnea | Respiratory, thoracic and mediastinal disorders | All Patients | 1 | 10 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | All Patients | ||
| Total, other adverse events | All Patients | 0 | 0 |
| Total, serious adverse events | All Patients | 1 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00538980
GET https://conductscience.org/api/trials/v1/NCT00538980/registered